Wealth Enhancement Advisory Services’s Spyre Therapeutics SYRE Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$258K	Buy	+3,227	New	+$310K	﹤0.01%	3505

Other funds holding SYRE

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return

Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return

CIA

Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Wealth Enhancement Advisory Services's SYRE Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 3,227 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #3505 among its holdings.

9 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

Wealth Enhancement Advisory Services held 3,227 shares of Spyre Therapeutics worth $258K as of Q3 2026.
Spyre Therapeutics was a new Wealth Enhancement Advisory Services position in Q3 2026.
Spyre Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3505 holding.
9 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.